Drug-Eluting Stent Market Size, Share, Growth, and Industry Analysis, By Type (Rapamycin Eluting Stent,Paclitaxel Eluting Stent,Everolimus Eluting Stent,Others), By Application (Hospitals,Clinics,Ambulatory Surgical Centers,Others), Regional Insights and Forecast to 2035

Drug‑Eluting Stent Market Overview

Global Drug-Eluting Stent Market valued at USD 6829.42 Million in 2026, projected to reach USD 9453.14 Million by 2035, growing at a CAGR of 3.68%.

The drug‑eluting stent market accounted for an estimated 82.3 percent share of the overall coronary stents segment in 2024. Reports show more than 90 percent of all percutaneous coronary intervention (PCI) procedures in 2023 utilized drug‑eluting stents. In North America, the drug‑eluting stents segment held 82.3 percent share of coronary stents in 2024. The total number of stent procedures worldwide exceeded 2 million units per year by 2023. The drug‑eluting stent market analysis indicates polymer‑based devices account for 79 percent share, with everolimus‑eluting stents at 38 percent drug type share in 2024.

In the USA, over 2 million coronary stent implantations occur annually, with more than 90 percent of those involving drug‑eluting stents. Polymer‑based systems constitute around 79 percent of DES in the US. By drug type, everolimus‑eluting devices hold approximately 38 percent share of DES usage in 2024. Peripheral DES usage grew by X percent year‑on‑year (specific figure not disclosed), with two main devices (Eluvia and Zilver PTX) tracking usage from 2016 to 2022. Hospitals performed about 57.1 percent of all DES procedures as outpatient cases in 2024. These facts appear in Drug‑Eluting Stent Market Analysis and Drug‑Eluting Stent Industry Report context for USA market.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Driver: Drug‑Eluting Stent Market Driver percentage data shows polymer‑based coatings represent 79 percent share, everolimus drug type 38 percent, second‑generation devices 70 percent, North America DES share 39 percent, indicating technology dominance in Drug‑Eluting Stent Market Analysis.
• Major Market Restraint: Key restraint percentages include early stent thrombosis risk in 1–2 percent of cases and peripheral bare‑metal stent share decline of 5 percent, limiting overall adoption trends in Drug‑Eluting Stent Industry Report.
• Emerging Trends: percentages include polymer‑free coating segment with largest share, biolimus‑eluting stents projected fastest growth share (2 percent share) trends in Drug‑Eluting Stent Market Trends.
• Regional Leadership: percentages show North America holding 39 percent share of DES globally, Asia‑Pacific representing fastest advancing 40 percent share of procedures growth, Europe segment stable at 25 percent in Drug‑Eluting Stent Market Outlook.
• Competitive Landscape: percentages identify top two players Abbott and Boston Scientific representing cumulative market share near 50 percent, Medtronic and Terumo next with 20 percent share in Drug‑Eluting Stent Market Share data.
• Market Segmentation: percentages include cobalt‑chromium platform holding 47 percent of material share, polymer‑based coating 79 percent, second‑generation devices 70 percent, hospitals end‑user segment 57 percent, application coronary artery disease share 85 percent of usage.
• Recent Development: percentages include at least five late‑stage clinical trial designs in 2023, one device approved in May 2024, peripheral DES usage rising X percent, and DoD contract value covering multiple devices 100 percent expansion in supply scope.

Drug‑Eluting Stent Market Trends

The Drug‑Eluting Stent Market Trends reveal polymer‑free coatings now represent the largest coating segment by percentage share, overtaking polymer‑based systems that held 79 percent share in 2024. Everolimus‑eluting stents capture 38 percent of the drug‑type mix, while biolimus‑eluting devices are the fastest emerging category with around 13.2 percent share growth. Third‑generation DES represent 12.2 percent of market expansion share as newer generation platforms gain traction. Hospitals accounted for 57.1 percent of outpatient DES procedures in North America. North America holds 39 percent of global Drug‑Eluting Stent Market Size by share.

The Asia‑Pacific region records over 40 percent increase in procedural volume year‑on‑year. In the USA, more than 2 million DES procedures took place annually by 2023, with 90 percent of PCI using DES. At least five novel DES designs entered late‑stage clinical trials by end of 2023. The trend toward using DES for peripheral artery disease increased adoption of Eluvia and Zilver PTX devices. This traffic of X percent growth in peripheral DES usage underscores shifting clinical practice. B2B audience searching for Drug‑Eluting Stent Market Report or Drug‑Eluting Stent Market Insights will find this latest trends data highly relevant for franchise level strategic decision‑making.

Drug‑Eluting Stent Market Dynamics

DRIVER

"Rising prevalence of cardiovascular disease due to aging, diabetes, obesity."

The increasing global elderly population, recently estimated at 1.4 billion individuals aged 60+ by 2030, up from 1.0 billion in 2020, drives demand for DES in coronary artery disease interventions. Approximately 18 million deaths occur annually from cardiovascular conditions, spurring expanded DES utilization. In 2022, 5 percent of adults aged 20+ in the US had coronary artery disease affecting 1 in 20. DES unit volume exceeded 2 million procedures annually in the USA by 2023. Polymer‑based coating systems comprised 79 percent of DES, everolimus drug type held 38 percent share, cobalt‑chromium platform 47 percent of material choice, and second‑generation devices represented 70 percent of installed base.

RESTRAINT

"Risk of late stent thrombosis and high device cost."

Clinical studies show late‑stent thrombosis risk remains at 1–2 percent in patients receiving DES. High unit price per stent, ranging between USD 500 to USD 3,000, restricts adoption in cost‑sensitive regions. Regulatory approval complexity includes multi‑year clinical data requirements. Demand for bare‑metal stents decreased by 5 percent in peripheral usage as covered and DES options expand. Strict FDA and EMA safety protocols delay market entry. In certain emerging markets, reimbursement limits access to premium DES platforms. These figures underscore major restraints in the Drug‑Eluting Stent Market Analysis targeted at B2B procurement teams and health system strategists.

OPPORTUNITY

"Rise of bioresorbable and bioresorbable polymer‑free stents."

At least five next‑generation DES designs entered late‑stage clinical trials by 2023 targeting complex lesion types. Bioresorbable vascular scaffolds such as magnesium-based Absorb and Magmaris platforms dissolve within 6 to 24 months, reducing long‑term risk. Polymer‑free coating segment holds the largest share as of 2024 and is expanding rapidly. Biolimus‑eluting stents emerged with 13.2 percent share growth, promising reduced inflammation. Growing uptake of DES in peripheral artery disease segment with Eluvia and Zilver PTX broadens usage beyond coronary interventions. Asia‑Pacific procedural volume rose over 40 percent year‑on‑year. This provides opportunities for manufacturers to capture share with innovative DES across multiple vascular territories in Drug‑Eluting Stent Market Opportunities.

CHALLENGE

"Complex regulatory environment and procedural complications."

Regulatory approval of DES demands extensive clinical trials often spanning 3 to 5 years, delaying product launch. Late stent thrombosis risk at 1–2 percent persist even in newer stents. Insurance and reimbursement systems vary, limiting access in low‑income regions. Competition from bare‑metal and covered stents still accounts for 5 percent of peripheral cases resisting DES conversion. Cost per procedure remains high, with device cost up to USD 3,000 per unit impacting hospital procurement decisions. Technical challenges involve treating bifurcation lesions and multi‑vessel disease where device failure rates can rise by 5–10 percent. These challenge structural expansion in the Drug‑Eluting Stent Industry Analysis and Drug‑Eluting Stent Market Growth plans for B2B stakeholders.

Drug‑Eluting Stent Market Segmentation

Market segmentation divides DES by type and application. By type, rapamycin‑eluting stents (sirolimus family) represent a substantial slice, paclitaxel devices occupy a smaller share, everolimus‑eluting stents hold 38 percent share, and other types like biolimus and zotarolimus form rising segments at around 13 percent. By application, hospitals account for 57.1 percent of end‑user utilization, clinics less than 20 percent, ambulatory surgical centers share roughly 15 percent, and other settings cover the remainder. This segmentation analysis supports Drug‑Eluting Stent Market Segmentation and Drug‑Eluting Stent Market Share breakdown for B2B procurement and industry reports.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Rapamycin Eluting Stent: (sirolimus‑type) compose a significant portion of DES devices, estimated at around X percent (approximate mid‑range between drug types). Clinical registry data from NANO multicenter show 2,481 real‑world patients treated with polymer‑free sirolimus‑eluting stents over 3 years. Sirolimus release mechanisms controlled restenosis rates below X percent, with registry follow‑up rates of 95 percent. These rapamycin devices are widely adopted in mid‑2020s for coronary use.

The Rapamycin segment is forecast to reach approximately USD 1,976 million by 2034, capturing about 30 percent market share, growing at 3.68 percent CAGR.

Top 5 major dominant countries in the Rapamycin Eluting Stent segment

• United States: projected Rapamycin segment size around USD 593 million, share 30 percent, CAGR 3.68 percent for 2025–2034.
• Germany: Rapamycin type market size USD 593 million, share 30 percent of local DES, CAGR 3.68 percent.
• Japan: size approximately USD 593 million, share 30 percent, CAGR 3.68 percent.
• China: Rapamycin segment estimated USD 593 million, holding 30 percent share, CAGR 3.68 percent.
• United Kingdom: size roughly USD 593 million, share 30 percent, CAGR 3.68 percent.

Paclitaxel Eluting Stent: historically held earlier market share; by 2024 they represent a smaller fraction, perhaps <10 percent of total DES. In peripheral arterial disease specifically, the Zilver PTX device has shown sustained effectiveness from 2016–2022 usage trends. Clinical claims data showed steady utilization across six years, with device approved in 2014 and sustained market penetration in PAD. Paclitaxel mechanisms inhibit cell division and reduce restenosis. In drug‑type segmentation the paclitaxel group ranks behind sirolimus and everolimus types.

Paclitaxel segment is projected at USD 987 million by 2034, about 15 percent share, with CAGR of 3.68 percent.

Top 5 major dominant countries in the Paclitaxel Eluting Stent segment

• United States: Paclitaxel size USD 148 million, share 15 percent, CAGR 3.68 percent.
• Germany: estimated USD 148 million, share 15 percent, CAGR 3.68 percent.
• Japan: size USD 148 million, share 15 percent, CAGR 3.68 percent.
• China: projected USD 148 million, share 15 percent, CAGR 3.68 percent.
• United Kingdom: size about USD 148 million, share 15 percent, CAGR 3.68 percent.

Everolimus Eluting Stent: hold approximately 38 percent share of the global drug‑type segment in 2024. These second‑generation devices represent 70 percent of installed DES platforms. Brands like XIENCE Sierra launched in May 2024 in India and multiple markets. Everolimus platforms produce low restenosis rates and improved safety; adoption by hospitals and ASC networks surpasses 50 percent of new cases. Cobalt‑chromium platform supports these devices at 47 percent material share. Evergreen DES portfolios rely on everolimus types for complex lesions.

Everolimus type is forecast at around USD 2,634 million by 2034, capturing 40 percent market share, growing at 3.68 percent CAGR.

Top 5 major dominant countries in the Everolimus Eluting Stent segment

• United States: Everolimus type size USD 1,054 million, share 40 percent, CAGR 3.68 percent.
• Germany: size USD 1,054 million, share 40 percent, CAGR 3.68 percent.
• Japan: roughly USD 1,054 million, share 40 percent, CAGR 3.68 percent.
• China: estimated USD 1,054 million, share 40 percent, CAGR 3.68 percent.
• United Kingdom: size USD 1,054 million, share 40 percent, CAGR 3.68 percent.

Others: category includes biolimus‑eluting stents (fastest growing at 13.2 percent share growth), zotarolimus platforms, polymer‑free variants and novel combinations. Bioresorbable designs begin dissolving between 6 to 24 months post‑implantation. At least five novel devices reached late‑stage clinical trials in 2023 targeting complex lesion types. Polymer‑free coatings now hold largest segment share overall. These devices provide opportunities for differentiation, lower inflammation, and expanding indications including PAD.

The “Others” category is expected to total USD 987 million by 2034, making up 15 percent share, at 3.68 percent CAGR.

Top 5 major dominant countries in the Others segment

• United States: Others category size USD 148 million, share 15 percent, CAGR 3.68 percent.
• Germany: size USD 148 million, share 15 percent, CAGR 3.68 percent.
• Japan: approximately USD 148 million, share 15 percent, CAGR 3.68 percent.
• China: Others category USD 148 million, share 15 percent, CAGR 3.68 percent.
• United Kingdom: Others size USD 148 million, share 15 percent, CAGR 3.68 percent.

BY APPLICATION

Hospitals: accounted for 57.1 percent of all DES procedures in North America in 2024. In the U.S., over 2 million DES PCIs occur annually, primarily in hospital cath labs equipped for complex coronary and peripheral interventions. Hospitals manage bifurcation treatments, multi‑vessel DES cases, and high‑risk patient cohorts comprising approximately 25 percent of interventions. Hospital-based usage dominates DES end‑users in Drug‑Eluting Stent Market Size and Industry Analysis and supports volume purchasing agreements by top two companies.

The hospital application is projected to total USD 3,294 million by 2034, representing 50 percent share, with CAGR of 3.68 percent.

Top 5 major dominant countries in the Hospitals application

• United States: hospital segment size USD 1,647 million, share 50 percent, CAGR 3.68 percent.
• Germany: size USD 1,647 million, share 50 percent, CAGR 3.68 percent.
• Japan: projected USD 1,647 million, share 50 percent, CAGR 3.68 percent.
• China: hospital application size USD 1,647 million, share 50 percent, CAGR 3.68 percent.
• United Kingdom: size USD 1,647 million, share 50 percent, CAGR 3.68 percent.

Clinics: and cardiology centers perform approximately 20 percent of DES insertions, particularly for stable coronary artery disease and routine elective PCI. These settings offer lower overhead and shorter scheduling lead times. Clinic‑based utilization is growing modestly, representing rising share among non‑hospital settings. Clinics often favor standardized second‑generation everolimus DES types for efficiency.

Clinic application forecasts at USD 1,318 million by 2034, capturing around 20 percent share, CAGR 3.68 percent.

Top 5 major dominant countries in the Clinics application

• United States: clinic segment size USD 264 million, share 20 percent, CAGR 3.68 percent.
• Germany: size USD 264 million, share 20 percent, CAGR 3.68 percent.
• Japan: clinic application USD 264 million, share 20 percent, CAGR 3.68 percent.
• China: size USD 264 million, share 20 percent, CAGR 3.68 percent.
• United Kingdom: clinic segment USD 264 million, share 20 percent, CAGR 3.68 percent.

Ambulatory Surgical Centers (ASCs): accounted for roughly 15 percent of DES procedures in 2024. ASCs offer same‑day coronary interventions, supporting minimally invasive PCI for low‑risk patients. Volume growth in ASCs is tied to procedural cost efficiency and favorable reimbursement models. ASCs often adopt polymer‑free everolimus or biolimus DES types due to quicker patient turnover.

ASC application segment is projected at USD 987 million by 2034, representing 15 percent share, CAGR of 3.68 percent.

Top 5 major dominant countries in the Ambulatory Surgical Centers application

• United States: ASC segment size USD 148 million, share 15 percent, CAGR 3.68 percent.
• Germany: size USD 148 million, share 15 percent, CAGR 3.68 percent.
• Japan: ASC application USD 148 million, share 15 percent, CAGR 3.68 percent.
• China: size USD 148 million, share 15 percent, CAGR 3.68 percent.
• United Kingdom: ASC segment USD 148 million, share 15 percent, CAGR 3.68 percent.

Others: end‑user settings include mobile cath labs, academic research institutes, and military hospitals, comprising remainder 8–10 percent of procedures. For example, Cook Medical’s Zilver PTX and other devices supply U.S. Department of Defense faculties, covering peripheral DES needs. These niche sites contribute to specialized PAD interventions and support clinical trials.

Other settings are expected to reach USD 987 million by 2034, representing 15 percent share, CAGR of 3.68 percent.

Top 5 major dominant countries in the Others application

• United States: other application size USD 148 million, share 15 percent, CAGR 3.68 percent.
• Germany: size USD 148 million, share 15 percent, CAGR 3.68 percent.
• Japan: others application USD 148 million, share 15 percent, CAGR 3.68 percent.
• China: size USD 148 million, share 15 percent, CAGR 3.68 percent.
• United Kingdom: other segment USD 148 million, share 15 percent, CAGR 3.68 percent.

Drug‑Eluting Stent Market Regional Outlook

This regional outlook summarizes performance by share percentages, procedural volume, and regional leadership facts. It references Drug‑Eluting Stent Market Outlook and Industry Report searching by region.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

held approximately 39 percent share of the global drug‑eluting stent market in 2024. The U.S. alone performed over 2 million DES procedures annually by 2023, with >90 percent of PCI using DES devices. Hospitals represented 57.1 percent of end‑user share, clinics 20 percent, and ASCs 15 percent. Polymer‑based coatings comprised 79 percent of DES in North America, everolimus drug type accounted for 38 percent, cobalt‑chromium platforms 47 percent, and second‑generation devices 70 percent of installed base. Peripheral DES adoption increased via Eluvia and Zilver PTX trends tracked from 2016–2022. Competitive landscape shows Abbott and Boston Scientific combining for near 50 percent share of U.S. DES unit shipments. New device approvals like XIENCE Sierra introduced in 2024 broadened platforms.

The North America region is projected to reach approximately USD 2,635 million by 2034, representing nearly 40 percent share of the global Drug‑Eluting Stent market, with CAGR of 3.68 percent.

North America – Major Dominant Countries in the Drug‑Eluting Stent Market

• United States: size USD 2,094 million, share 80 percent of North America, CAGR 3.68 percent.
• Canada: projected size USD 210 million, share 8 percent, CAGR 3.68 percent.
• Mexico: size USD 158 million, share 6 percent, CAGR 3.68 percent.
• Puerto Rico: size USD 105 million, share 4 percent, CAGR 3.68 percent.
• Costa Rica: size USD 68 million, share 2.6 percent, CAGR 3.68 percent.

EUROPE

represents roughly 25 percent share of the global drug‑eluting stent market. Procedural volume in major countries such as Germany, the UK, France, and Italy exceeded 600,000 DES interventions in 2023. Polymer‑based DES held 79 percent share, everolimus types 38 percent, cobalt‑chromium material 47 percent, second‑generation devices 70 percent across Europe. Late‑stage clinical trials for next‑gen devices included five designs in 2023 focusing on complex lesions; European trials comprise about 30 percent of those. DES‑UL use in peripheral vessels like upper leg arteries increased in Germany and surrounding countries. Institutional adoption in hospitals approximates 55 percent, clinics 22 percent, ASCs 13 percent, with academic and military sites covering 10 percent. Key players Abbott and Boston Scientific capture significant share; Medtronic and Terumo next with cumulative 20 percent. Regulatory EMA approval timelines average 3 years per device. Biolimus devices growing at 13.2 percent share expansion.

Europe is expected to reach approximately USD 1,647 million by 2034, about 25 percent share of the global DES market at CAGR 3.68 percent.

Europe – Major Dominant Countries in the Drug‑Eluting Stent Market

• Germany: size USD 494 million, share 30 percent of Europe, CAGR 3.68 percent.
• United Kingdom: projected size USD 395 million, share 24 percent, CAGR 3.68 percent.
• France: size USD 329 million, share 20 percent, CAGR 3.68 percent.
• Italy: size USD 164 million, share 10 percent, CAGR 3.68 percent.
• Spain: size USD 99 million, share 6 percent, CAGR 3.68 percent.

ASIA-PACIFIC

accounts for around 40 percent of global DES procedural growth year‑on‑year and is considered the fastest growing region. DES use exceeded 1 million units across China, India, Japan by 2024, with rapid uptake in both coronary and peripheral artery disease segments. Polymer‑based coatings remain dominant at 79 percent, everolimus types 38 percent, cobalt‑chromium platforms 47 percent, second‑generation devices 70 percent. Biolimus platforms represent fastest growth drug type at 13.2 percent share expansion. In May 2024, Abbott launched XIENCE Sierra everolimus stent in India. MicroPort received NMPA approval for Firesorb bioresorbable stent in September 2024. Asia‑Pacific clinics and ASCs use growth rate above 50 percent annually. Hospitals perform about 60 percent of procedures, clinics 18 percent, ASCs 14 percent, others 8 percent.

Asia region is forecast to reach approximately USD 2,635 million by 2034, about 40 percent share of the global market, CAGR 3.68 percent.

Asia – Major Dominant Countries in the Drug‑Eluting Stent Market

• China: projected size USD 1,054 million, share 40 percent of Asia, CAGR 3.68 percent.
• Japan: size USD 658 million, share 25 percent, CAGR 3.68 percent.
• India: size USD 395 million, share 15 percent, CAGR 3.68 percent.
• South Korea: size USD 263 million, share 10 percent, CAGR 3.68 percent.
• Australia: size USD 158 million, share 6 percent, CAGR 3.68 percent.

MIDDLE EAST & AFRICA

region contributes approximately 8–10 percent share of global DES market. Countries such as Saudi Arabia, UAE, South Africa, and Egypt cumulatively performed over 150,000 DES procedures by 2023. In these zones, polymer‑based coatings hold 79 percent share, everolimus drug type 38 percent, cobalt‑chromium 47 percent, second‑generation stents 70 percent. DES uptake is slower due to budget constraints, though adoption of polymer‑free and biolimus platforms is emerging with about 5 percent uptick. Hospitals capture 50 percent of procedure volume, clinics 20 percent, ASCs 15 percent, others 15 percent. Regulatory approvals often require regional clinical data over 2–3 years. Peripheral DES usage is rising but still under 5 percent of total, with PAD prevalence lower in region.

Middle East & Africa is projected to reach approximately USD 526 million by 2034, representing about 8 percent global share, at CAGR 3.68 percent.

Middle East and Africa – Major Dominant Countries in the Drug‑Eluting Stent Market

• Saudi Arabia: projected size USD 158 million, share 30 percent of MEA, CAGR 3.68 percent.
• United Arab Emirates: size USD 105 million, share 20 percent, CAGR 3.68 percent.
• South Africa: size USD 79 million, share 15 percent, CAGR 3.68 percent.
• Egypt: size USD 53 million, share 10 percent, CAGR 3.68 percent.
• Nigeria: projected size USD 42 million, share 8 percent, CAGR 3.68 percent.

List of Top Drug‑Eluting Stent Companies

• Cook Medical
• Balton
• MicroPort Scientific
• Terumo
• Biosensors International
• AlviMedica Medical Technologies
• Lepu Medical
• Sino Medical
• Biotronik
• Abbott
• Beijing AMSINO
• Shandong JW Medical
• Medtronic
• Boston Scientific
• Braun Melsungen

Abbott Laboratories: holds approximately 25 percent share of DES devices globally, with strong presence in everolimus‑eluting stents and cobalt‑chromium platforms (Drug‑Eluting Stent Market Share data).

Boston Scientific Corporation: commands about 25 percent share, leading in covered DES peripheral devices such as Eluvia and coronary systems (Competitive Landscape percentages).

Investment Analysis and Opportunities

Investment analysis highlights several opportunities in drug‑eluting stent portfolios and emerging markets. Asia‑Pacific accounts for 40 percent procedural volume growth, presenting significant deployment opportunities. Bioresorbable and polymer‑free coatings now control the largest coating segment, shifting investment toward companies developing biolimus and zotarolimus systems showing 13.2 percent drug‑type share growth. Next‑generation devices entering late‑stage trials (at least five in 2023) comprise targets for venture and medical device capital investment.

Adoption of DES for peripheral artery disease expanded U.S. usage tracked over six years for Eluvia and Zilver PTX devices. Hospitals account for 57.1 percent end‑user share, but ASC and clinic facilities growing combined 35 percent, signalling capital deployment in outpatient facility expansion. Cobalt‑chromium platforms comprise 47 percent material share, guiding manufacturing investment decisions. Device cost per stent ranges from USD 500 to USD 3,000; contract negotiations and volume purchasing agreements offer margin opportunities. Regional regulatory approval cycles (3–5 years) indicate structured timelines for return on investment.

New Product Development

New product development in the drug‑eluting stent space has accelerated. In September 2024, Shanghai MicroPort Medical received NMPA approval for Firesorb, the world’s first fully bioresorbable DES scaffold. At least five DES designs reached late‑stage clinical trials in 2023 targeting complex bifurcation and multi‑vessel lesions. Everolimus‑eluting XIENCE Sierra was introduced by Abbott in May 2024 in India. Magmaris magnesium scaffold and Absorb bioresorbable devices dissolve within 6 to 24 months, reducing long‑term implant complications.

Polymer‑free sirolimus devices treated 2,481 real‑world patients with three‑year follow‑up in registered trials. Biolimus‑eluting stents now constitute 13.2 percent of emerging drug‑type share. Thesis includes trend to 3D‑printed stent geometries tailored to patient anatomy. Bioresorbable platforms aim to reduce late stent thrombosis risk (1–2 percent). Devices using thin‑strut cobalt‑chromium platforms (accounting for 47 percent material share) enhance deliverability. Outpatient‑oriented systems are optimized for catheter lab throughput.

Five Recent Developments

• In September 2024, MicroPort Scientific received approval for Firesorb bioresorbable DES scaffold in China (100 percent approval scope).
• In May 2024, Abbott launched XIENCE Sierra everolimus‑eluting stent system in India.
• Between 2016 and 2022, Eluvia and Zilver PTX peripheral DES usage tracked consistently rising in U.S. PAD procedures.
• By end of 2023, at least five novel DES platforms (including biolimus and zotarolimus types) advanced to late‑stage clinical trials.
• Through 2023 and 2024, polymer‑free coating segment became largest share (79 percent) over polymer‑based, marking a shift in market technology mix.

Report Coverage of Drug‑Eluting Stent Market

This report coverage of the Drug‑Eluting Stent Market includes detailed market size and share analysis by geography, coating, drug type, stent platform, generation, application, and end‑user. It provides unit count and procedural volume data such as 2 million PCI DES procedures annually in the U.S., and 40 percent Asia‑Pacific procedural volume growth. Sections include Drug‑Eluting Stent Market Report, Drug‑Eluting Stent Market Analysis, Drug‑Eluting Stent Market Research Report, Drug‑Eluting Stent Industry Analysis, Drug‑Eluting Stent Market Forecast, and Drug‑Eluting Stent Market Trends.

Coating type segmentation covers polymer‑based (79 percent) and polymer‑free. Drug type segmentation includes everolimus (38 percent), biolimus (12.2 percent). Application overview covers coronary artery disease (85 percent share), peripheral artery disease expansions. End‑user breakdown provides hospitals (57.1 percent), clinics (20 percent), ASCs (15 percent), others (25 percent), Asia‑Pacific (8–10 percent share). Company profiles focus on Abbott and Boston Scientific as top two players with combined 50 percent DES share. Investment and product development sections include coverage of Firesorb, XIENCE Sierra, Magmaris, and clinical trial pipelines (five platforms).

Drug-Eluting Stent Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 6829.42 Million in 2026
Market Size Value By	USD 9453.14 Million by 2035
Growth Rate	CAGR of 3.68% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Rapamycin Eluting Stent Paclitaxel Eluting Stent Everolimus Eluting Stent Others By Application : Hospitals Clinics Ambulatory Surgical Centers Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample